Float Short %

3.12

Margin Of Safety %

Put/Call OI Ratio

0.25

EPS Next Q Diff

0.02

EPS Last/This Y

-0.07

EPS This/Next Y

-0.05

Price

4.14

Target Price

6.67

Analyst Recom

Performance Q

58.53

Relative Volume

0.66

Beta

1.48

Ticker: IMAB

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	IMAB	4.86	0.22	0.15	5569
2025-08-18	IMAB	5.12	0.19	0.17	3868
2025-08-19	IMAB	4.27	0.19	0.32	3967
2025-08-20	IMAB	4.55	0.20	0.05	4285
2025-08-21	IMAB	4.73	0.19	0.04	4516
2025-08-22	IMAB	5.11	0.19	0.03	4534
2025-08-25	IMAB	4.78	0.15	0.07	6137
2025-08-26	IMAB	5.15	0.16	0.06	6535
2025-08-27	IMAB	4.48	0.16	0.19	6587
2025-08-28	IMAB	4.28	0.17	0.03	6541
2025-08-29	IMAB	4.16	0.17	0.03	6604
2025-09-02	IMAB	4.33	0.16	0.13	6935
2025-09-03	IMAB	4.63	0.16	0.09	6945
2025-09-04	IMAB	4.36	0.16	0.00	6964
2025-09-05	IMAB	4.41	0.16	0.07	6966
2025-09-08	IMAB	4.28	0.16	0.64	6952
2025-09-09	IMAB	4.62	0.17	0.00	7197
2025-09-10	IMAB	4.23	0.17	0.96	7289
2025-09-11	IMAB	3.95	0.25	0.00	8044
2025-09-12	IMAB	4.08	0.25	0.00	8058
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	IMAB	4.85	-	-	-0.20
2025-08-18	IMAB	5.09	-	-	-0.20
2025-08-19	IMAB	4.21	-	-	-0.20
2025-08-20	IMAB	4.49	-	-	-0.20
2025-08-21	IMAB	4.72	-	-	-0.20
2025-08-22	IMAB	5.18	-	-	-0.23
2025-08-25	IMAB	4.80	-	-	-0.23
2025-08-26	IMAB	5.18	-	-	-0.23
2025-08-28	IMAB	4.25	-	-	-0.23
2025-08-29	IMAB	4.16	-	-	-0.23
2025-09-02	IMAB	4.32	-	-	-0.34
2025-09-03	IMAB	4.64	-	-	-0.34
2025-09-04	IMAB	4.35	-	-	-0.34
2025-09-05	IMAB	4.38	-	-	-0.34
2025-09-08	IMAB	4.27	-	-	-0.34
2025-09-09	IMAB	4.61	-	-	-0.34
2025-09-10	IMAB	4.22	-	-	-0.34
2025-09-11	IMAB	3.90	-	-	-0.34
2025-09-12	IMAB	4.14	-	-	-0.34
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	IMAB	0.00	-35.70	0.80
2025-08-18	IMAB	0.00	-29.53	0.80
2025-08-19	IMAB	0.00	-29.53	0.80
2025-08-20	IMAB	0.00	-29.53	0.80
2025-08-21	IMAB	0.00	-29.53	0.80
2025-08-22	IMAB	0.00	-29.53	0.80
2025-08-25	IMAB	0.00	9.81	0.79
2025-08-26	IMAB	0.00	9.81	0.79
2025-08-27	IMAB	0.00	9.81	2.70
2025-08-28	IMAB	0.00	9.81	2.70
2025-08-29	IMAB	0.00	9.81	2.70
2025-09-02	IMAB	0.00	9.81	2.70
2025-09-03	IMAB	0.00	9.81	2.70
2025-09-04	IMAB	0.00	9.81	2.70
2025-09-05	IMAB	0.00	9.81	2.70
2025-09-08	IMAB	0.00	9.81	2.70
2025-09-09	IMAB	0.00	9.81	2.70
2025-09-10	IMAB	0.00	9.81	2.70
2025-09-11	IMAB	0.00	9.81	3.12
2025-09-12	IMAB	0.00	9.81	3.12
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.07

Avg. EPS Est. Current Quarter

-0.05

Avg. EPS Est. Next Quarter

-0.05

Insider Transactions

Institutional Transactions

9.81

Beta

1.48

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

95.2

Max Drawdown 5-Year %

-99.3

Target Price

6.67

P/E

Forward P/E

PEG

P/S

P/B

1.65

P/Free Cash Flow

EPS

-0.71

Average EPS Est. Cur. Y

-0.34

EPS Next Y. (Est.)

-0.39

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.66

Return on Equity vs Sector %

-45.2

Return on Equity vs Industry %

-32

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.15

EBIT Estimation

I-MAB

Sector: Healthcare

Industry: Biotechnology

Employees: 32

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

stock quote shares IMAB – I-Mab ADR Stock Price stock today

news today IMAB – I-Mab ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch IMAB – I-Mab ADR yahoo finance google finance

stock history IMAB – I-Mab ADR invest stock market

stock prices IMAB premarket after hours

ticker IMAB fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: IMAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y